Targeting fibroblast growth factor/Fibroblast growth factor receptor system in angiogenesis

Antiangiogenic Cancer Therapy

Volumn , Issue , 2007, Pages 189-224

  Rusnati, Marco ^a   Presta, Marco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85055589156     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420004298     Document Type: Chapter

References (334)

1. Carmeliet, P. and Jain, R.K., Angiogenesis in cancer and other diseases, Nature, 407, 249, 2000.
2. Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other disease, Nat Med, 1, 27, 1995.
3. Shing, Y. et al., Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor, Science, 223, 1296, 1984.
4. Maciag, T. et al., Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain, Science, 225, 932, 1984.
5. Carmeliet, P., Mechanisms of angiogenesis and arteriogenesis, Nat Med, 6, 389, 2000.
6. Itoh, N. and Ornitz, D.M., Evolution of the Fgf and Fgfr gene families, Trends Genet, 20, 563, 2004.
7. Presta, M. et al., Fibroblast growth factor=fibroblast growth factor receptor system in angiogenesis, Cytokine Growth Factor Rev, 16, 159, 2005.
8. Javerzat, S., Auguste, P., and Bikfalvi, A., The role of fibroblast growth factors in vascular development, Trends Mol Med, 8, 483, 2002.
9. Cross, M.J. and Claesson-Welsh, L., FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition, Trends Pharmacol Sci, 22, 201, 2001.
10. Mattila, M.M. et al., FGF-8b increases angiogenic capacity and tumor growth of androgenregulated S115 breast cancer cells, Oncogene, 20, 2791, 2001.
11. Liotta, L.A., Steeg, P.S., and Stetler-Stevenson, W.G., Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation, Cell, 64, 327, 1991.
12. Hiraoka, N. et al., Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins, Cell, 95, 365, 1998.
13. Rusnati, M. et al., A distinct basic fibroblast growth factor (FGF-2)=FGF receptor interaction distinguishes urokinase-type plasminogen activator induction from mitogenicity in endothelial cells, Mol Biol Cell, 7, 369, 1996.
14. Taraboletti, G. et al., Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells, Am J Pathol, 160, 673, 2002.
15. Terranova, V.P. et al., Human endothelial cells are chemotactic to endothelial cell growth factor and heparin, J Cell Biol, 101, 2330, 1985.
16. Stokes, C.L. et al., Chemotaxis of human microvessel endothelial cells in response to acidic fibroblast growth factor, Lab Invest, 63, 657, 1990.
17. Shono, T. et al., Inhibition of FGF-2-mediated chemotaxis of murine brain capillary endothelial cells by cyclic RGDfV peptide through blocking the redistribution of c-Src into focal adhesions, Exp Cell Res, 268, 169, 2001.
18. Montesano, R., Orci, L., and Vassalli, P., In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices, J Cell Biol, 97, 1648, 1983.
19. Montesano, R. et al., Basic fibroblast growth factor induces angiogenesis in vitro, Proc Natl Acad Sci USA, 83, 7297, 1986.
20. Pepper, M.S. et al., Transforming growth factor-beta 1 modulates basic fibroblast growth factorinduced proteolytic and angiogenic properties of endothelial cells in vitro, J Cell Biol, 111, 743, 1990.
21. Henke, C.A. et al., CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix, J Clin Invest, 97, 2541, 1996.
22. Takei, A. et al., Effects of fibrin on the angiogenesis in vitro of bovine endothelial cells in collagen gel, In Vitro Cell Dev Biol Anim, 31, 467, 1995.
23. Kumar, R. et al., Regulation of distinct steps of angiogenesis by different angiogenic molecules, Int J Oncol, 12, 749, 1998.
24. Davis, G.E. and Camarillo, C.W., Regulation of endothelial cell morphogenesis by integrins, mechanical forces, and matrix guidance pathways, Exp Cell Res, 216, 113, 1995.
25. Sheibani, N., Newman, P.J., and Frazier, W.A., Thrombospondin-1, a natural inhibitor of angiogenesis, regulates platelet-endothelial cell adhesion molecule-1 expression and endothelial cell morphogenesis, Mol Biol Cell, 8, 1329, 1997.
26. Schnaper, H.W. et al., Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro, J Cell Physiol, 156, 235, 1993.
27. Schnaper, H.W. et al., Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways, J Cell Physiol, 165, 107, 1995.
28. Underwood, P.A., Bean, P.A., and Gamble, J.R., Rate of endothelial expansion is controlled by cell:cell adhesion, Int J Biochem Cell Biol, 34, 55, 2002.
29. Hoying, J.B. and Williams, S.K., Effects of basic fibroblast growth factor on human microvessel endothelial cell migration on collagen I correlates inversely with adhesion and is cell density dependent, J Cell Physiol, 168, 294, 1996.
30. Klein, S. et al., Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells, Mol Biol Cell, 4, 973, 1993.
31. Collo, G. and Pepper, M.S., Endothelial cell integrin alpha 5 beta 1 expression is modulated by cytokines and during migration in vitro, J Cell Sci, 112 (Pt 4), 569, 1999.
32. Sepp, N.T. et al., Basic fibroblast growth factor increases expression of the alpha v beta 3 integrin complex on human microvascular endothelial cells, J Invest Dermatol, 103, 295, 1994.
33. Zhou, L. et al., Divergent effects of extracellular oxygen on the growth, morphology, and function of human skin microvascular endothelial cells, J Cell Physiol, 182, 134, 2000.
34. Gerritsen, M.E. et al., Branching out: a molecular fingerprint of endothelial differentiation into tube-like structures generated by Affymetrix oligonucleotide arrays, Microcirculation, 10, 63, 2003.
35. Garlanda, C. and Dejana, E., Heterogeneity of endothelial cells. Specific markers, Arterioscler Thromb Vasc Biol, 17, 1193, 1997.
36. McCarthy, S.A. et al., Heterogeneity of the endothelial cell and its role in organ preference of tumour metastasis, Trends Pharmacol Sci, 12, 462, 1991.
37. Chi, J.T. et al., Endothelial cell diversity revealed by global expression profiling, Proc Natl Acad Sci USA, 100, 10623, 2003.
38. Ribatti, D. et al., The chick embryo chorioallantoic membrane as a model for in vivo research on anti-angiogenesis, Curr Pharm Biotechnol, 1, 73, 2000.
39. Herbert, J.M., Laplace, M.C., and Maffrand, J.P., Effect of heparin on the angiogenic potency of basic and acidic fibroblast growth factors in the rabbit cornea assay, Int J Tissue React, 10, 133, 1988.
40. Seghezzi, G. et al., Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis, J Cell Biol, 141, 1659, 1998.
41. Passaniti, A. et al., A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor, Lab Invest, 67, 519, 1992.
42. Liekens, S. et al., Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir, Cancer Res, 61, 5057, 2001.
43. Ribatti, D. et al., Cell-mediated delivery of fibroblast growth factor-2 and vascular endothelial growth factor onto the chick chorioallantoic membrane: endothelial fenestration and angiogenesis, J Vasc Res, 38, 389, 2001.
44. Rusnati, M. et al., Alpha v beta 3 integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells, Mol Biol Cell, 8, 2449, 1997.
45. Tanghetti, E. et al., Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts, Oncogene, 21, 3889, 2002.
46. Rusnati, M. et al., Cell membrane GM1 ganglioside is a functional coreceptor for fibroblast growth factor 2, Proc Natl Acad Sci USA, 99, 4367, 2002.
47. Johnson, D.E. and Williams, L.T., Structural and functional diversity in the FGF receptor multigene family, Adv Cancer Res, 60, 1, 1993.
48. Gonzalez, A.M. et al., Distribution of fibroblast growth factor (FGF)-2 and FGF receptor-1 messenger RNA expression and protein presence in the mid-trimester human fetus, Pediatr Res, 39, 375, 1996.
49. Arany, E. and Hill, D.J., Fibroblast growth factor-2 and fibroblast growth factor receptor-1 mRNA expression and peptide localization in placentae from normal and diabetic pregnancies, Placenta, 19, 133, 1998.
50. Yoon, S.Y., Tefferi, A., and Li, C.Y., Cellular distribution of platelet-derived growth factor, transforming growth factor-beta, basic fibroblast growth factor, and their receptors in normal bone marrow, Acta Haematol, 104, 151, 2000.
51. Ribatti, D. et al., New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge=chorioallantoic membrane assay, J Vasc Res, 34, 455, 1997.
52. Dell’Era, P. et al., Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells, Oncogene, 20, 2655, 2001.
53. Lindahl, U. et al., More to “heparin” than anticoagulation, Thromb Res, 75, 1, 1994.
54. Pellegrini, L., Role of heparan sulfate in fibroblast growth factor signalling: a structural view, Curr Opin Struct Biol, 11, 629, 2001.
55. Eriksson, A.E. et al., Three-dimensional structure of human basic fibroblast growth factor, Proc Natl Acad Sci USA, 88, 3441, 1991.
56. Rusnati, M. and Presta, M., Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization, Int J Clin Lab Res, 26, 15, 1996.
57. Horowitz, A., Tkachenko, E., and Simons, M., Fibroblast growth factor-specific modulation of cellular response by syndecan-4, J Cell Biol, 157, 715, 2002.
58. Rusnati, M., Urbinati, C., and Presta, M., Internalization of basic fibroblast growth factor (bFGF) in cultured endothelial cells: role of the low affinity heparin-like bFGF receptors, J Cell Physiol, 154, 152, 1993.
59. Hsia, E., Richardson, T.P., and Nugent, M.A., Nuclear localization of basic fibroblast growth factor is mediated by heparan sulfate proteoglycans through protein kinase C signaling, J Cell Biochem, 88, 1214, 2003.
60. Gospodarowicz, D. and Cheng, J., Heparin protects basic and acidic FGF from inactivation, J Cell Physiol, 128, 475, 1986.
61. Coltrini, D. et al., Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor, Biochem J, 303 (Pt 2), 583, 1994.
62. Presta, M. et al., Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form, J Cell Physiol, 140, 68, 1989.
63. Vlodavsky, I. et al., Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis, Cancer Metastasis Rev, 9, 203, 1990.
64. Ribatti, D. et al., In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2, J Cell Sci, 112 (Pt 23), 4213, 1999.
65. Ruegg, C. and Mariotti, A., Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis, Cell Mol Life Sci, 60, 1135, 2003.
66. Eliceiri, B.P., Integrin and growth factor receptor crosstalk, Circ Res, 89, 1104, 2001.
67. Kumar, C.C., Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis, Curr Drug Targets, 4, 123, 2003.
68. Sahni, A. and Francis, C.W., Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires avb3, Blood, 104, 3635, 2004.
69. Presta, M. et al., Antiangiogenic activity of semisynthetic biotechnological heparins. Low-molecularweight- sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists, Arterioscler Thromb Vasc Biol, 25, 71, 2005.
70. Salmivirta, M., Heino, J., and Jalkanen, M., Basic fibroblast growth factor-syndecan complex at cell surface or immobilized to matrix promotes cell growth, J Biol Chem, 267, 17606, 1992.
71. Birkle, S. et al., Role of tumor-associated gangliosides in cancer progression, Biochimie, 85, 455, 2003.
72. Rusnati, M. et al., Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides:biochemical characterization and biological consequences in endothelial cell cultures, Mol Biol Cell, 10, 313, 1999.
73. Eswarakumar, V.P., Lax, I., and Schlessinger, J., Cellular signaling by fibroblast growth factor receptors, Cytokine Growth Factor Rev, 16, 139, 2005.
74. Schlaepfer, D.D., Hauck, C.R., and Sieg, D.J., Signaling through focal adhesion kinase, Prog Biophys Mol Biol, 71, 435, 1999.
75. Kumar, C.C., Signaling by integrin receptors, Oncogene, 17, 1365, 1998.
76. Palazzo, A.F. et al., Localized stabilization of microtubules by integrin- and FAK-facilitated Rho signaling, Science, 303, 836, 2004.
77. Zhai, J. et al., Direct interaction of focal adhesion kinase with p190RhoGEF, J Biol Chem, 278, 24865, 2003.
78. Sharma-Walia, N. et al., Kaposi’s sarcoma-associated herpesvirus=human herpesvirus 8 envelope glycoprotein gB induces the integrin-dependent focal adhesion kinase-Src-phosphatidylinositol 3-kinase-rho GTPase signal pathways and cytoskeletal rearrangements, J Virol, 78, 4207, 2004.
79. Scatena, M. et al., NF-kappaB mediates alpha v beta 3 integrin-induced endothelial cell survival, J Cell Biol, 141, 1083, 1998.
80. Chua, C.C. et al., Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2, Circ Res, 94, 316, 2004.
81. Miljan, E.A. and Bremer, E.G., Regulation of growth factor receptors by gangliosides, Sci STKE, 2002, RE15, 2002.
82. Gualandris, A. et al., Basic fibroblast growth factor overexpression in endothelial cells:anautocrine mechanism for angiogenesis and angioproliferative diseases, Cell Growth Differ, 7, 147, 1996.
83. Bikfalvi, A. et al., Differential modulation of cell phenotype by different molecular weight forms of basic fibroblast growth factor: possible intracellular signaling by the high molecular weight forms, J Cell Biol, 129, 233, 1995.
84. Florkiewicz, R.Z., Baird, A., and Gonzalez, A.M., Multiple forms of bFGF: differential nuclear and cell surface localization, Growth Factors, 4, 265, 1991.
85. Quarto, N. et al., Selective expression of high molecular weight basic fibroblast growth factor confers a unique phenotype to NIH 3T3 cells, Cell Regul, 2, 699, 1991.
86. Tille, J.C. et al., Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGFand basic fibroblast growth factor-induced angiogenesis in vivo and in vitro, J Pharmacol Exp Ther, 299, 1073, 2001.
87. Kanda, S., Miyata, Y., and Kanetake, H., Fibroblast growth factor-2-mediated capillary morphogenesis of endothelial cells requires signals via Flt-1=vascular endothelial growth factor receptor-1:possible involvement of c-Akt, J Biol Chem, 279, 4007, 2004.
88. Jia, H. et al., Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF, Biochem Biophys Res Commun, 283, 164, 2001.
89. Tomanek, R.J. et al., Vascular endothelial growth factor and basic fibroblast growth factor differentially modulate early postnatal coronary angiogenesis, Circ Res, 88, 1135, 2001.
90. Xue, L. and Greisler, H.P., Angiogenic effect of fibroblast growth factor-1 and vascular endothelial growth factor and their synergism in a novel in vitro quantitative fibrin-based 3-dimensional angiogenesis system, Surgery, 132, 259, 2002.
91. Castellon, R. et al., Effects of angiogenic growth factor combinations on retinal endothelial cells, Exp Eye Res, 74, 523, 2002.
92. Pepper, M.S. and Mandriota, S.J., Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells, Exp Cell Res, 241, 414, 1998.
93. Nico, B. et al., In vivo absence of synergism between fibroblast growth factor-2 and vascular endothelial growth factor, J Hematother Stem Cell Res, 10, 905, 2001.
94. Wang, Y. and Becker, D., Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth, Nat Med, 3, 887, 1997.
95. Cassinelli, G. et al., Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer, Clin Cancer Res, 8, 2647, 2002.
96. Hotchkiss, K.A. et al., Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center, Mol Cancer Ther, 1, 1191, 2002.
97. Ciardiello, F. et al., Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor, Clin Cancer Res, 7, 1459, 2001.
98. Ginns, L.C. et al., Pulmonary capillary hemangiomatosis with atypical endotheliomatosis:successful antiangiogenic therapy with doxycycline, Chest, 124, 2017, 2003.
99. Jee, S.H. et al., Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK=STAT3 and PI3-kinase=Akt pathways, J Invest Dermatol, 123, 1169, 2004.
100. Huang, S. et al., Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells, Oncogene, 21, 2504, 2002.
101. Sasamura, H. et al., Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma, Br J Cancer, 86, 768, 2002.
102. Fujimoto, J. et al., Plausible novel therapeutic strategy of uterine endometrial cancer with reduction of basic fibroblast growth factor secretion by progestin and O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470), Cancer Lett, 113, 187, 1997.
103. Shao, Z.M. et al., Curcumin exerts multiple suppressive effects on human breast carcinoma cells, Int J Cancer, 98, 234, 2002.
104. Sartippour, M.R. et al., Inhibition of fibroblast growth factors by green tea, Int J Oncol, 21, 487, 2002.
105. Lee, H.T. et al., FGF-2 induced by interleukin-1 beta through the action of phosphatidylinositol 3-kinase mediates endothelial mesenchymal transformation in corneal endothelial cells, J Biol Chem, 279, 32325, 2004.
106. Albuquerque, M.L., Akiyama, S.K., and Schnaper, H.W., Basic fibroblast growth factor release by human coronary artery endothelial cells is enhanced by matrix proteins, 17beta-estradiol, and a PKC signaling pathway, Exp Cell Res, 245, 163, 1998.
107. Yoshida, S. et al., Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis, Mol Cell Biol, 17, 4015, 1997.
108. Faris, M. et al., Inflammatory cytokines induce the expression of basic fibroblast growth factor (bFGF) isoforms required for the growth of Kaposi’s sarcoma and endothelial cells through the activation of AP-1 response elements in the bFGF promoter, Aids, 12, 19, 1998.
109. Khachigian, L.M., Early growth response-1: blocking angiogenesis by shooting the messenger, Cell Cycle, 3, 10, 2004.
110. Wijelath, E.S. et al., Oncostatin M induces basic fibroblast growth factor expression in endothelial cells and promotes endothelial cell proliferation, migration and spindle morphology, J Cell Sci, 110 (Pt 7), 871, 1997.
111. Maier, J.A. et al., Tumor-necrosis-factor-induced fibroblast growth factor-1 acts as a survival factor in a transformed endothelial cell line, Am J Pathol, 149, 945, 1996.
112. Danesi, R. et al., Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane, Br J Cancer, 68, 932, 1993.
113. Ensoli, B. et al., Block of AIDS-Kaposi’s sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS, J Clin Invest, 94, 1736, 1994.
114. Ribatti, D. et al., Inhibition of neuroblastoma-induced angiogenesis by fenretinide, Int J Cancer, 94, 314, 2001.
115. Tsou, R. and Isik, F.F., Integrin activation is required for VEGF and FGF receptor protein presence on human microvascular endothelial cells, Mol Cell Biochem, 224, 81, 2001.
116. Fujiwara, Y. and Kaji, T., Possible mechanism for lead inhibition of vascular endothelial cell proliferation: a lower response to basic fibroblast growth factor through inhibition of heparan sulfate synthesis, Toxicology, 133, 147, 1999.
117. Zhang, W. et al., Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells, Blood, 103, 1185, 2004.
118. Aviezer, D. et al., Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA, Mol Cell Biol, 17, 1938, 1997.
119. Wang, S. et al., QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis, Proc Natl Acad Sci USA, 101, 4833, 2004.
120. Cieslak, M. et al., DNAzymes to beta 1 and beta 3 mRNA down-regulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in fibrin and matrigel, J Biol Chem, 277, 6779, 2002.
121. Presta, M. et al., Heparin derivatives as angiogenesis inhibitors, Curr Pharm Des, 9, 553, 2003.
122. Barzu, T. et al., Heparin-derived oligosaccharides: affinity for acidic fibroblast growth factor and effect on its growth-promoting activity for human endothelial cells, J Cell Physiol, 140, 538, 1989.
123. Foxall, C. et al., Sulfated malto-oligosaccharides bind to basic FGF, inhibit endothelial cell proliferation, and disrupt endothelial cell tube formation, J Cell Physiol, 168, 657, 1996.
124. Herbert, J.M. et al., Activity of pentosan polysulphate and derived compounds on vascular endothelial cell proliferation and migration induced by acidic and basic FGF in vitro, Biochem Pharmacol, 37, 4281, 1988.
125. Ishihara, M. et al., Structural features in heparin which modulate specific biological activities mediated by basic fibroblast growth factor, Glycobiology, 4, 451, 1994.
126. Gagliardi, A.R., Taylor, M.F., and Collins, D.C., Uptake of suramin by human microvascular endothelial cells, Cancer Lett, 125, 97, 1998.
127. Kitajima, I., Unoki, K., and Maruyama, I., Phosphorothioate oligodeoxynucleotides inhibit basic fibroblast growth factor-induced angiogenesis in vitro and in vivo, Antisense Nucleic Acid Drug Dev, 9, 233, 1999.
128. Leali, D. et al., Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives, J Biol Chem, 276, 37900, 2001.
129. Urbinati, C. et al., Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists, FEBS Lett, 568, 171, 2004.
130. Ensoli, B. et al., Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi’s sarcoma, Nature, 371, 674, 1994.
131. Giavazzi, R. et al., Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis, Am J Pathol, 162, 1913, 2003.
132. Rusnati, M. et al., Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat, J Biol Chem, 276, 22420, 2001.
133. Marshall, J.L. et al., Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer, Clin Cancer Res, 3, 2347, 1997.
134. Swain, S.M. et al., Phase I trial of pentosan polysulfate, Invest New Drugs, 13, 55, 1995.
135. Schwartsmann, G. et al., Phase II study of pentosan polysulfate (PPS) in patients with AIDSrelated Kaposi’s sarcoma, Tumori, 82, 360, 1996.
136. Sola, F. et al., The antitumor efficacy of cytotoxic drugs is potentiated by treatment with PNU 145156E, a growth-factor-complexing molecule, Cancer Chemother Pharmacol, 43, 241, 1999.
137. Zacharski, L.R. and Loynes, J.T., Low-molecular-weight heparin in oncology, Anticancer Res, 23, 2789, 2003.
138. Ziche, M. et al., Angiogenesis can be stimulated or repressed in vivo by a change in GM3:GD3 ganglioside ratio, Lab Invest, 67, 711, 1992.
139. Neufeld, G. and Gospodarowicz, D., Protamine sulfate inhibits mitogenic activities of the extracellular matrix and fibroblast growth factor, but potentiates that of epidermal growth factor, J Cell Physiol, 132, 287, 1987.
140. Bornstein, P. et al., Thrombospondin 2, a matricellular protein with diverse functions, Matrix Biol, 19, 557, 2000.
141. Taraboletti, G. et al., The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor, Cell Growth Differ, 8, 471, 1997.
142. Margosio, B. et al., Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2, Blood, 102, 4399, 2003.
143. Dawson, D.W. et al., Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat, Mol Pharmacol, 55, 332, 1999.
144. Bossard, C. et al., Antiangiogenic properties of fibstatin, an extracellular FGF-2-binding polypeptide, Cancer Res, 64, 7507, 2004.
145. Asplin, I.R. et al., Differential regulation of the fibroblast growth factor (FGF) family by alpha(2)-macroglobulin: evidence for selective modulation of FGF-2-induced angiogenesis, Blood, 97, 3450, 2001.
146. Mathew, S. et al., Characterization of the interaction between alpha2-macroglobulin and fibroblast growth factor-2: the role of hydrophobic interactions, Biochem J, 374, 123, 2003.
147. Dennis, P.A. et al., Alpha 2-macroglobulin is a binding protein for basic fibroblast growth factor, J Biol Chem, 264, 7210, 1989.
148. Bottazzi, B. et al., Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component, J Biol Chem, 272, 32817, 1997.
149. Breviario, F. et al., Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component, J Biol Chem, 267, 22190, 1992.
150. Rusnati, M. et al., Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis, Blood, 104, 92, 2004.
151. Salustri, A. et al., PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization, Development, 131, 1577, 2004.
152. Miao, R.Q. et al., Kallistatin is a new inhibitor of angiogenesis and tumor growth, Blood, 100, 3245, 2002.
153. Russo, K. et al., Platelet-derived growth factor-BB and basic fibroblast growth factor directly interact in vitro with high affinity, J Biol Chem, 277, 1284, 2002.
154. De Marchis, F. et al., Platelet-derived growth factor inhibits basic fibroblast growth factor angiogenic properties in vitro and in vivo through its alpha receptor, Blood, 99, 2045, 2002.
155. Perollet, C. et al., Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization, Blood, 91, 3289, 1998.
156. Lozano, R.M. et al., Solution structure and interaction with basic and acidic fibroblast growth factor of a 3-kDa human platelet factor-4 fragment with antiangiogenic activity, J Biol Chem, 276, 35723, 2001.
157. Sulpice, E. et al., Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway, Blood, 100, 3087, 2002.
158. Brown, K.J. and Parish, C.R., Histidine-rich glycoprotein and platelet factor 4 mask heparan sulfate proteoglycans recognized by acidic and basic fibroblast growth factor, Biochemistry, 33, 13918, 1994.
159. Hagedorn, M. et al., Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors, Cancer Res, 62, 6884, 2002.
160. Hagedorn, M. et al., A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2, FASEB J, 15, 550, 2001.
161. Jouan, V. et al., Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action, Blood, 94, 984, 1999.
162. Spinetti, G. et al., The chemokine CXCL13 (BCA-1) inhibits FGF-2 effects on endothelial cells, Biochem Biophys Res Commun, 289, 19, 2001.
163. Shellenberger, T.D. et al., BRAK=CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells, Cancer Res, 64, 8262, 2004.
164. Hanneken, A. and Baird, A., Soluble forms of the high-affinity fibroblast growth factor receptor in human vitreous fluid, Invest Ophthalmol Vis Sci, 36, 1192, 1995.
165. Hanneken, A., Maher, P.A., and Baird, A., High affinity immunoreactive FGF receptors in the extracellular matrix of vascular endothelial cells-implications for the modulation of FGF-2, J Cell Biol, 128, 1221, 1995.
166. Bergonzoni, L. et al., Characterization of a biologically active extracellular domain of fibroblast growth factor receptor 1 expressed in Escherichia coli, Eur J Biochem, 210, 823, 1992.
167. Ueno, H. et al., A truncated form of fibroblast growth factor receptor 1 inhibits signal transduction by multiple types of fibroblast growth factor receptor, J Biol Chem, 267, 1470, 1992.
168. Schilling-Schon, A. et al., The role of endogenous growth factors to support corneal endothelial migration after wounding in vitro, Exp Eye Res, 71, 583, 2000.
169. Facchiano, A. et al., Identification of a novel domain of fibroblast growth factor 2 controlling its angiogenic properties, J Biol Chem, 278, 8751, 2003.
170. Presta, M. et al., Biologically active synthetic fragments of human basic fibroblast growth factor (bFGF): identification of two Asp-Gly-Arg-containing domains involved in the mitogenic activity of bFGF in endothelial cells, J Cell Physiol, 149, 512, 1991.
171. Kumar, C.C. et al., Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist, Cancer Res, 61, 2232, 2001.
172. Friedlander, M. et al., Definition of two angiogenic pathways by distinct alpha v integrins, Science, 270, 1500, 1995.
173. Yeh, C.H. et al., Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v) beta(3) blockade of endothelial cells, Mol Pharmacol, 59, 1333, 2001.
174. Ding, L. et al., Inhibition of cell migration and angiogenesis by the amino-terminal fragment of 24kD basic fibroblast growth factor, J Biol Chem, 277, 31056, 2002.
175. Plum, S.M. et al., Generation of a specific immunological response to FGF-2 does not affect wound healing or reproduction, Immunopharmacol Immunotoxicol, 26, 29, 2004.
176. Baird, A., Mormede, P., and Bohlen, P., Immunoreactive fibroblast growth factor (FGF) in a transplantable chondrosarcoma: inhibition of tumor growth by antibodies to FGF, J Cell Biochem, 30, 79, 1986.
177. Hori, A. et al., Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor, Cancer Research, 51, 6180, 1991.
178. Talarico, D. et al., Protection of mice against tumor growth by immunization with an oncogeneencoded growth factor, Proc Natl Acad Sci USA, 87, 4222, 1990.
179. He, Q.M. et al., Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice, J Biol Chem, 278, 21831, 2003.
180. Seo, D.W. et al., TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism, Cell, 114, 171, 2003.
181. Gatto, C. et al., BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity, Clin Cancer Res, 5, 3603, 1999.
182. Min, H.Y. et al., Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice, Cancer Res, 56, 2428, 1996.
183. Blei, F. et al., Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis, J Cell Physiol, 155, 568, 1993.
184. Thorpe, P.E., Vascular targeting agents as cancer therapeutics, Clin Cancer Res, 10, 415, 2004.
185. Tozer, G.M. et al., Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues, Cancer Res, 59, 1626, 1999.
186. Tozer, G.M. et al., Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability, Cancer Res, 61, 6413, 2001.
187. Tozer, G.M. et al., The biology of the combretastatins as tumour vascular targeting agents, Int J Exp Pathol, 83, 21, 2002.
188. Vacca, A. et al., Antiangiogenesis is produced by nontoxic doses of vinblastine, Blood, 94, 4143, 1999.
189. Ahmed, B. et al., Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity, Int J Cancer, 105, 20, 2003.
190. Belleri, M. et al., Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,40-trimethoxystilbene, Mol Pharmacol, 67, 1451, 2005.
191. Belotti, D. et al., The microtubule-affecting drug paclitaxel has antiangiogenic activity, Clin Cancer Res, 2, 1843, 1996.
192. Taraboletti, G. et al., Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative, Clin Cancer Res, 8, 1182, 2002.
193. Abe, M. et al., Goniodomin A, an antifungal polyether macrolide, exhibits antiangiogenic activities via inhibition of actin reorganization in endothelial cells, J Cell Physiol, 190, 109, 2002.
194. Siemann, D.W. et al., Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy, Int J Cancer, 99, 1, 2002.
195. Siim, B.G. et al., Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA), Cancer Chemother Pharmacol, 51, 43, 2003.
196. Wildiers, H. et al., Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence, Eur J Cancer, 40, 284, 2004.
197. Kwon, H.J. et al., Betulinic acid inhibits growth factor-induced in vitro angiogenesis via the modulation of mitochondrial function in endothelial cells, Jpn J Cancer Res, 93, 417, 2002.
198. Chow, L.M. et al., Anti-angiogenic potential of Gleditsia sinensis fruit extract, Int J Mol Med, 12, 269, 2003.
199. Liu, Y. et al., Citrus pectin: characterization and inhibitory effect on fibroblast growth factorreceptor interaction, J Agric Food Chem, 49, 3051, 2001.
200. Tong, Y. et al., Philinopside A, a novel marine-derived compound possessing dual anti-angiogenic and anti-tumor effects, Int J Cancer, 114, 843, 2005.
201. Tong, Y. et al., Anti-angiogenic effects of Shiraiachrome A, a compound isolated from a Chinese folk medicine used to treat rheumatoid arthritis, Eur J Pharmacol, 494, 101, 2004.
202. Brakenhielm, E., Cao, R., and Cao, Y., Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes, FASEB J, 15, 1798, 2001.
203. Hoffman, R., Burns, W.W., 3rd, and Paper, D.H., Selective inhibition of cell proliferation and DNA synthesis by the polysulphated carbohydrate l-carrageenan, Cancer Chemother Pharmacol, 36, 325, 1995.
204. Dupont, E. et al., Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue, Clin Exp Metastasis, 19, 145, 2002.
205. Klauber, N. et al., New activity of spironolactone. Inhibition of angiogenesis in vitro and in vivo, Circulation, 94, 2566, 1996.
206. Koyama, S. et al., Tranilast inhibits protein kinase C-dependent signalling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells, Br J Pharmacol, 127, 537, 1999.
207. Wood, J. et al., Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid, J Pharmacol Exp Ther, 302, 1055, 2002.
208. Pai, R. et al., Indomethacin inhibits endothelial cell proliferation by suppressing cell cycle proteins and PRB phosphorylation: a key to its antiangiogenic action? Mol Cell Biol Res Commun, 4, 111, 2000.
209. Vincent, L. et al., Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models, Arterioscler Thromb Vasc Biol, 22, 623, 2002.
210. Klein-Soyer, C. et al., SR 25989 inhibits healing of a mechanical wound of confluent human saphenous vein endothelial cells which is modulated by standard heparin and growth factors, J Cell Physiol, 160, 316, 1994.
211. Chen, W. et al., Control of angiogenesis by inhibitor of phospholipase A2, Chin Med Sci J, 19, 6, 2004.
212. Aguzzi, M.S. et al., RGDS peptide induces caspase 8 and caspase 9 activation in human endothelial cells, Blood, 103, 4180, 2004.
213. Mohan, R. et al., Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B, J Biol Chem, 275, 10405, 2000.
214. Keledjian, K., Garrison, J.B., and Kyprianou, N., Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion, J Cell Biochem, 94, 374, 2005.
215. Gelati, M. et al., Effects of thalidomide on parameters involved in angiogenesis: an in vitro study, J Neurooncol, 64, 193, 2003.
216. Gagliardi, A.R., Hennig, B., and Collins, D.C., Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors, Anticancer Res, 16, 1101, 1996.
217. Ashino-Fuse, H. et al., Medroxyprogesterone acetate, an anti-cancer and anti-angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells, Int J Cancer, 44, 859, 1989.
218. Nakashio, A., Fujita, N., and Tsuruo, T., Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway, Int J Cancer, 98, 36, 2002.
219. Taraboletti, G. et al., Antiangiogenic activity of aplidine, a new agent of marine origin, Br J Cancer, 90, 2418, 2004.
220. Presta, M. et al., Anti-angiogenic activity of the purine analog 6-thioguanine, Leukemia, 16, 1490, 2002.
221. Basaki, Y. et al., UFT and its metabolites inhibit cancer-induced angiogenesis. Via a VEGFrelated pathway, Oncology (Huntingt), 14, 68, 2000.
222. Yamayoshi, T. et al., Expression of keratinocyte growth factor=fibroblast growth factor-7 and its receptor in human lung cancer: correlation with tumour proliferative activity and patient prognosis, J Pathol, 204, 110, 2004.
223. Dorkin, T.J. et al., FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease, Oncogene, 18, 2755, 1999.
224. Gnanapragasam, V.J. et al., FGF8 isoform b expression in human prostate cancer, Br J Cancer, 88, 1432, 2003.
225. Heer, R. et al., Fibroblast growth factor 17 is over-expressed in human prostate cancer, J Pathol, 204, 578, 2004.
226. Auguste, P. et al., Inhibition of fibroblast growth factor=fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms, Cancer Res, 61, 1717, 2001.
227. Polnaszek, N. et al., Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer, Cancer Res, 63, 5754, 2003.
228. Hagedorn, M. and Bikfalvi, A., Target molecules for anti-angiogenic therapy: from basic research to clinical trials, Crit Rev Oncol Hematol, 34, 89, 2000.
229. Ziche, M., Donnini, S., and Morbidelli, L., Development of new drugs in angiogenesis, Curr Drug Targets, 5, 485, 2004.
230. Patel, S.R. et al., Pilot study of vitaxin-an angiogenesis inhibitor-in patients with advanced leiomyosarcomas, Cancer, 92, 1347, 2001.
231. Posey, J.A. et al., A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer, Cancer Biother Radiopharm, 16, 125, 2001.
232. Heryanto, B., Lipson, K.E., and Rogers, P.A., Effect of angiogenesis inhibitors on oestrogenmediated endometrial endothelial cell proliferation in the ovariectomized mouse, Reproduction, 125, 337, 2003.
233. Abdollahi, A. et al., SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro, Cancer Res, 63, 3755, 2003.
234. Wang, L.L. et al., Antitumor activities of a novel indolin-2-ketone compound, Z24: more potent inhibition on bFGF-induced angiogenesis and bcl-2 over-expressing cancer cells, Eur J Pharmacol, 502, 1, 2004.
235. Laird, A.D. et al., SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors, Cancer Res, 60, 4152, 2000.
236. Dimitroff, C.J. et al., Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy, Invest New Drugs, 17, 121, 1999.
237. Beebe, J.S. et al., Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy, Cancer Res, 63, 7301, 2003.
238. Klint, P. et al., Contribution of Src and Ras pathways in FGF-2 induced endothelial cell differentiation, Oncogene, 18, 3354, 1999.
239. Alavi, A. et al., Role of Raf in vascular protection from distinct apoptotic stimuli, Science, 301, 94, 2003.
240. Giuliani, R. et al., Role of endothelial cell extracellular signal-regulated kinase1=2 in urokinasetype plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2, J Cell Sci, 112 (Pt 15), 2597, 1999.
241. Pintucci, G. et al., Induction of stromelysin-1 (MMP-3) by fibroblast growth factor-2 (FGF-2) in FGF-2_=_ microvascular endothelial cells requires prolonged activation of extracellular signalregulated kinases-1 and -2 (ERK-1=2), J Cell Biochem, 90, 1015, 2003.
242. Naik, M.U., Vuppalanchi, D., and Naik, U.P., Essential role of junctional adhesion molecule-1 in basic fibroblast growth factor-induced endothelial cell migration, Arterioscler Thromb Vasc Biol, 23, 2165, 2003.
243. Shono, T., Kanetake, H., and Kanda, S., The role of mitogen-activated protein kinase activation within focal adhesions in chemotaxis toward FGF-2 by murine brain capillary endothelial cells, Exp Cell Res, 264, 275, 2001.
244. Eliceiri, B.P. et al., Integrin alpha v beta 3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis, J Cell Biol, 140, 1255, 1998.
245. Bhagwat, S.V. et al., The angiogenic regulator CD13=APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis, Blood, 101, 1818, 2003.
246. Kuzuya, M. et al., Induction of apoptotic cell death in vascular endothelial cells cultured in threedimensional collagen lattice, Exp Cell Res, 248, 498, 1999.
247. Santiago, F.S. et al., Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2, Am J Pathol, 154, 937, 1999.
248. Hata, Y., Rook, S.L., and Aiello, L.P., Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44=p42 mitogen-activated protein kinase-dependent pathway, Diabetes, 48, 1145, 1999.
249. Langford, D. et al., Signalling crosstalk in FGF2-mediated protection of endothelial cells from HIV-gp120, BMC Neurosci, 6, 8, 2005.
250. Zubilewicz, A. et al., Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: a comparative study with VEGF, Oncogene, 20, 1403, 2001.
251. Tanaka, K., Abe, M., and Sato, Y., Roles of extracellular signal-regulated kinase 1=2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis, Jpn J Cancer Res, 90, 647, 1999.
252. Gu, Q. et al., Basic fibroblast growth factor inhibits radiation-induced apoptosis of HUVECs. I. The PI3K=AKT pathway and induction of phosphorylation of BAD, Radiat Res, 161, 692, 2004.
253. Rieck, P.W., Cholidis, S., and Hartmann, C., Intracellular signaling pathway of FGF-2-modulated corneal endothelial cell migration during wound healing in vitro, Exp Eye Res, 73, 639, 2001.
254. Kay, E.P. et al., Fibroblast growth factor 2 uses PLC-gamma1 for cell proliferation and PI3-kinase for alteration of cell shape and cell proliferation in corneal endothelial cells, Mol Vis, 4, 22, 1998.
255. Lee, H.T. and Kay, E.P., FGF-2 induced reorganization and disruption of actin cytoskeleton through PI 3-kinase, Rho, and Cdc42 in corneal endothelial cells, Mol Vis, 9, 624, 2003.
256. Lu, L. et al., Role of the Src homology 2 domain-containing protein Shb in murine brain endothelial cell proliferation and differentiation, Cell Growth Differ, 13, 141, 2002.
257. Kent, K.C. et al., Requirement for protein kinase C activation in basic fibroblast growth factorinduced human endothelial cell proliferation, Circ Res, 77, 231, 1995.
258. Presta, M. et al., Basic fibroblast growth factor requires a long-lasting activation of protein kinase C to induce cell proliferation in transformed fetal bovine aortic endothelial cells, Cell Regul, 2, 719, 1991.
259. Presta, M. et al., Basic fibroblast growth factor: production, mitogenic response, and post-receptor signal transduction in cultured normal and transformed fetal bovine aortic endothelial cells, J Cell Physiol, 141, 517, 1989.
260. Presta, M., Maier, J.A., and Ragnotti, G., The mitogenic signaling pathway but not the plasminogen activator-inducing pathway of basic fibroblast growth factor is mediated through protein kinase C in fetal bovine aortic endothelial cells, J Cell Biol, 109, 1877, 1989.
261. Haimovitz-Friedman, A. et al., Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis, Cancer Res, 54, 2591, 1994.
262. Takano, S. et al., A diaminoantraquinone inhibitor of angiogenesis, J Pharmacol Exp Ther, 271, 1027, 1994.
263. Hu, D.E. and Fan, T.P., Protein kinase C inhibitor calphostin C prevents cytokine-induced angiogenesis in the rat, Inflammation, 19, 39, 1995.
264. van Hinsbergh, V.W. et al., Genistein reduces tumor necrosis factor alpha-induced plasminogen activator inhibitor-1 transcription but not urokinase expression in human endothelial cells, Blood, 84, 2984, 1994.
265. Koroma, B.M. and de Juan, E., Jr., Phosphotyrosine inhibition and control of vascular endothelial cell proliferation by genistein, Biochem Pharmacol, 48, 809, 1994.
266. Kilarski, W.W., Jura, N., and Gerwins, P., Inactivation of Src family kinases inhibits angiogenesis in vivo: implications for a mechanism involving organization of the actin cytoskeleton, Exp Cell Res, 291, 70, 2003.
267. Tsuda, S. et al., Role of c-Fyn in FGF-2-mediated tube-like structure formation by murine brain capillary endothelial cells, Biochem Biophys Res Commun, 290, 1354, 2002.
268. Lee, H.T., Kim, T.Y., and Kay, E.P., Cdk4 and p27Kip1 play a role in PLC-gamma1- mediated mitogenic signaling pathway of 18 kDa FGF-2 in corneal endothelial cells, Mol Vis, 8, 17, 2002.
269. Sa, G. and Fox, P.L., Basic fibroblast growth factor-stimulated endothelial cell movement is mediated by a pertussis toxin-sensitive pathway regulating phospholipase A2 activity, J Biol Chem, 269, 3219, 1994.
270. Anwar, K.N. et al., RhoA=Rho-associated kinase pathway selectively regulates thrombin-induced intercellular adhesion molecule-1 expression in endothelial cells via activation of I kappa B kinase beta and phosphorylation of RelA=p65, J Immunol, 173, 6965, 2004.
271. Soriano, J.V. et al., Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain bound antagonists, Mol Cancer Ther, 3, 1289, 2004.
272. D’Angelo, G., Lee, H., and Weiner, R.I., cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation, J Cell Biochem, 67, 353, 1997.
273. Forough, R. et al., Role of AKT=PKB signaling in fibroblast growth factor-1 (FGF-1)- induced angiogenesis in the chicken chorioallantoic membrane (CAM), J Cell Biochem, 94, 109, 2005.
274. Hoffmann, S. et al., Carboxyamido-triazole modulates retinal pigment epithelial and choroidal endothelial cell attachment, migration, proliferation, and MMP-2 secretion of choroidal endothelial cells, Curr Eye Res, 30, 103, 2005.
275. Cross, M.J. et al., Tyrosine 766 in the fibroblast growth factor receptor-1 is required for FGF-stimulation of phospholipase C, phospholipase D, phospholipase A(2), phosphoinositide 3-kinase and cytoskeletal reorganisation in porcine aortic endothelial cells, J Cell Sci, 113 (Pt 4), 643, 2000.
276. Lee, S.H., Schloss, D.J., and Swain, J.L., Maintenance of vascular integrity in the embryo requires signaling through the fibroblast growth factor receptor, J Biol Chem, 275, 33679, 2000.
277. Hood, J.D. et al., Differential alpha v integrin-mediated Ras-ERK signaling during two pathways of angiogenesis, J Cell Biol, 162, 933, 2003.
278. Mettouchi, A. et al., Integrin-specific activation of Rac controls progression through the G(1) phase of the cell cycle, Mol Cell, 8, 115, 2001.
279. Wary, K.K., Signaling through Raf-1 in the neovasculature and target validation by nanoparticles, Mol Cancer, 2, 27, 2003.
280. Rikitake, Y. et al., Lysophosphatidylcholine inhibits endothelial cell migration and proliferation via inhibition of the extracellular signal-regulated kinase pathway, Arterioscler Thromb Vasc Biol, 20, 1006, 2000.
281. Cross, M.J. et al., The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras=MEK=MAPK pathway via FRS2 phosphorylation in endothelial cells, Mol Biol Cell, 13, 2881, 2002.
282. Murakami, M. et al., Protein kinase C (PKC) delta regulates PKC alpha activity in a Syndecan-4- dependent manner, J Biol Chem, 277, 20367, 2002.
283. Kanda, S. et al., The nonreceptor protein-tyrosine kinase c-Fes is involved in fibroblast growth factor-2-induced chemotaxis of murine brain capillary endothelial cells, J Biol Chem, 275, 10105, 2000.
284. Tan, J. and Hallahan, D.E., Growth factor-independent activation of protein kinase B contributes to the inherent resistance of vascular endothelium to radiation-induced apoptotic response, Cancer Res, 63, 7663, 2003.
285. Klein, S. et al., Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation, Mol Cell Biol, 22, 5912, 2002.
286. Pourtier-Manzanedo, A. et al., Expression of an Ets-1 dominant-negative mutant perturbs normal and tumor angiogenesis in a mouse ear model, Oncogene, 22, 1795, 2003.
287. Kasbauer, C.W., Paper, D.H., and Franz, G., Sulfated beta-(1!4)-galacto-oligosaccharides and their effect on angiogenesis, Carbohydr Res, 330, 427, 2001.
288. Miao, H.Q. et al., Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound, J Clin Invest, 99, 1565, 1997.
289. Giraux, J.L. et al., Modulation of human endothelial cell proliferation and migration by fucoidan and heparin, Eur J Cell Biol, 77, 352, 1998.
290. Chabut, D. et al., Low molecular weight fucoidan and heparin enhance the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfate-dependent alpha 6 overexpression, Mol Pharmacol, 64, 696, 2003.
291. Bocci, G. et al., Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo, Cancer Chemother Pharmacol, 43, 205, 1999.
292. Sola, F. et al., Endothelial cells overexpressing basic fibroblast growth factor (FGF-2) induce vascular tumors in immunodeficient mice, Angiogenesis, 1, 102, 1997.
293. Gagliardi, A.R. et al., Antiangiogenic and antiproliferative activity of suramin analogues, Cancer Chemother Pharmacol, 41, 117, 1998.
294. Takano, S. et al., Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator, Cancer Res, 54, 2654, 1994.
295. Ciomei, M. et al., New sulfonated distamycin A derivatives with bFGF complexing activity, Biochem Pharmacol, 47, 295, 1994.
296. Braddock, P.S. et al., A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions, Br J Cancer, 69, 890, 1994.
297. Finch, P.W. et al., Inhibition of growth factor mitogenicity and growth of tumor cell xenografts by a sulfonated distamycin A derivative, Pharmacology, 55, 269, 1997.
298. Zugmaier, G., Lippman, M.E., and Wellstein, A., Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals, J Natl Cancer Inst, 84, 1716, 1992.
299. Aviezer, D. et al., Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis, Cancer Res, 60, 2973, 2000.
300. Presta, M. et al., Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecularweight- sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists, Arterioscler Thromb Vasc Biol, 25, 71, 2005.
301. Benelli, U. et al., The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization, Exp Eye Res, 67, 133, 1998.
302. Casu, B. et al., Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors, Biochemistry, 41, 10519, 2002.
303. Casu, B. et al., Undersulfated and glycol-split heparins endowed with antiangiogenic activity, J Med Chem, 47, 838, 2004.
304. Liekens, S. et al., Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds, Mol Pharmacol, 56, 204, 1999.
305. Liekens, S. et al., The sulfonic acid polymers PAMPS [poly(2-acrylamido-2-methyl-1-propanesulfonic acid)] and related analogues are highly potent inhibitors of angiogenesis, Oncol Res, 9, 173, 1997.
306. Sakairi, N. et al., Synthesis and biological evaluation of 2-amino-2-deoxy- and 6-amino-6-deoxycyclomaltoheptaose polysulfates as synergists for angiogenesis inhibition, Bioorg Med Chem, 4, 2187, 1996.
307. Gagliardi, A.R. and Collins, D.C., Inhibition of angiogenesis by aurintricarboxylic acid, Anticancer Res, 14, 475, 1994.
308. Matou, S. et al., Effect of an oversulfated exopolysaccharide on angiogenesis induced by fibroblast growth factor-2 or vascular endothelial growth factor in vitro, Biochem Pharmacol, 69, 751, 2005.
309. Hoffman, R. and Sykes, D., Inhibition of binding of basic fibroblast growth factor to low and high affinity receptors by carrageenans, Biochem Pharmacol, 45, 2348, 1993.
310. Patel, S., Leal, A.D., and Gorski, D.H., The homeobox gene Gax inhibits angiogenesis through inhibition of nuclear factor-kappaB-dependent endothelial cell gene expression, Cancer Res, 65, 1414, 2005.
311. Hanafusa, H. et al., Sprouty1 and Sprouty2 provide a control mechanism for the Ras=MAPK signalling pathway, Nat Cell Biol, 4, 850, 2002.
312. Kaur, G. et al., Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin:an orally bioavailable heat shock protein 90 modulator, Clin Cancer Res, 10, 4813, 2004.
313. Kroon, M.E. et al., Collagen type 1 retards tube formation by human microvascular endothelial cells in a fibrin matrix, Angiogenesis, 5, 257, 2002.
314. Staton, C.A. et al., Alphastatin, a 24-amino acid fragment of human fibrinogen, is a potent new inhibitor of activated endothelial cells in vitro and in vivo, Blood, 103, 601, 2004.
315. Dixelius, J. et al., Endostatin regulates endothelial cell adhesion and cytoskeletal organization, Cancer Res, 62, 1944, 2002.
316. Dixelius, J. et al., Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis, Blood, 95, 3403, 2000.
317. Guan, X. et al., Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells, Thromb Haemost, 92, 403, 2004.
318. Ashton, A.W. et al., Thromboxane A2 receptor agonists antagonize the proangiogenic effects of fibroblast growth factor-2: role of receptor internalization, thrombospondin-1, and alpha (v) beta 3, Circ Res, 94, 735, 2004.
319. Redlitz, A., Daum, G., and Sage, E.H., Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells, J Vasc Res, 36, 28, 1999.
320. Duenas, Z. et al., Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules, Invest Ophthalmol Vis Sci, 40, 2498, 1999.
321. Kanda, S. et al., Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis, J Natl Cancer Inst, 94, 1311, 2002.
322. Baiguera, S. et al., Ghrelin inhibits in vitro angiogenic activity of rat brain microvascular endothelial cells, Int J Mol Med, 14, 849, 2004.
323. Zhang, J.C. et al., The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin, Proc Natl Acad Sci USA, 99, 12224, 2002.
324. Kim, J. et al., IL-4 inhibits cell cycle progression of human umbilical vein endothelial cells by affecting p53, p21(Waf1), cyclin D1, and cyclin E expression, Mol Cells, 16, 92, 2003.
325. Angiolillo, A.L. et al., Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo, J Exp Med, 182, 155, 1995.
326. Kanda, S. et al., Pigment epithelium-derived factor inhibits fibroblast-growth-factor-2-induced capillary morphogenesis of endothelial cells through Fyn, J Cell Sci, 118, 961, 2005.
327. Kaur, B. et al., Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor, Oncogene, 24, 3632, 2005.
328. Pike, S.E. et al., Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth, J Exp Med, 188, 2349, 1998.
329. Guo, Y.L., Wang, S., and Colman, R.W., Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells, Arterioscler Thromb Vasc Biol, 21, 1427, 2001.
330. Lafleur, M.A. et al., Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs), J Cell Sci, 115, 3427, 2002.
331. Norioka, K. et al., Interaction of interleukin-1 and interferon-gamma on fibroblast growth factorinduced angiogenesis, Jpn J Cancer Res, 85, 522, 1994.
332. Sato, N. et al., Actions of TNF and IFN-gamma on angiogenesis in vitro, J Invest Dermatol, 95, 85S, 1990.
333. Grant, M.B., Caballero, S., and Millard, W.J., Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization, Regul Pept, 48, 267, 1993.
334. Kessler, O. et al., Semaphorin-3F is an inhibitor of tumor angiogenesis, Cancer Res, 64, 1008, 2004.